Related Experiment Video

Updated: May 20, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Pharmacological prevention and treatment of vascular dementia: approaches and perspectives

Andrius Baskys1, Jin-xiang Cheng

  • 1Alzheimer's Disease Prevention and Treatment Center, Orange, California, USA. abaskys@gmail.com

Experimental Gerontology
|July 17, 2012
PubMed

Insights

Effective treatment for vascular dementia (VaD) is lacking. Early hypertension management may reduce VaD risk, but other common treatments show limited efficacy, necessitating novel drug development strategies.

Area of Science:

  • Neurology
  • Gerontology
  • Pharmacology

Background:

  • Vascular dementia (VaD) is a prevalent cause of cognitive decline.
  • Currently, no approved pharmacological treatments exist for VaD prevention or management.
  • Understanding VaD's complex etiology is crucial for therapeutic development.

Purpose of the Study:

  • To review current therapeutic strategies for vascular dementia.
  • To evaluate the efficacy of existing treatments for hypertension, hyperlipidemia, and clotting abnormalities in VaD.
  • To identify gaps and future directions in VaD drug development.

Main Methods:

  • Systematic review of published clinical trial reports on VaD treatments.
  • Analysis of pharmacological interventions targeting hypertension, hyperlipidemia, and coagulation.
  • Assessment of Alzheimer's dementia (AD) medications in VaD patients.

Main Results:

  • Early hypertension treatment is associated with reduced VaD risk and slower progression.
  • Statin therapy for hyperlipidemia and aspirin for clotting disorders show no significant effect on VaD.
  • AD medications offer minor cognitive benefits in VaD, likely via co-existing AD pathology.

Conclusions:

  • Hypertension management is key for VaD risk reduction.
  • Existing treatments for hyperlipidemia and clotting disorders are ineffective for VaD.
  • Novel therapeutic approaches, including genotype-based patient stratification, are essential for effective VaD drug development.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...